Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms HELP
Based on 32,387 articles published since 2008
|||| 50 

These are the 32387 published articles about Pancreatic Neoplasms that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
376 Editorial EUS for pancreas cysts: what should we be sampling? 2013

Sreenarasimhaiah, Jayaprakash. · ·Dig Dis Sci · Pubmed #23504352.

ABSTRACT: -- No abstract --

377 Editorial EUS elastography: is it replacing or supplementing tissue acquisition? 2013

Deprez, Pierre H. · ·Gastrointest Endosc · Pubmed #23498142.

ABSTRACT: -- No abstract --

378 Editorial The Art in Science of microTAS. 2013

Gaitan, Michael / Minhas, Harp. · ·Lab Chip · Pubmed #23478673.

ABSTRACT: -- No abstract --

379 Editorial Advancements in the management of pancreatic cancer: 2013. 2013

Saif, Muhammad Wasif. · ·JOP · Pubmed #23474549.

ABSTRACT: Pancreatic cancer still remains a significant, unresolved therapeutic challenge and is the most lethal type of gastrointestinal cancer with a 5-year survival rate of 5%. Adjuvant chemotherapy remains to be gemcitabine alone, though fluorouracil offers the same survival and role of radiation remains controversial. Nevertheless, only a few patients survive for at least 5 years after R0 resection and adjuvant therapy. Borderline resectable pancreatic cancer remains an area that requires multi-disciplinary approach. Neo-adjuvant therapy very likely plays a role to downstage to a resectable state in these subgroup patients. There are different treatment approaches to locally advanced pancreatic cancer management, including single or multi-agent chemotherapy, chemotherapy followed by chemoradiation, or immediate concurrent chemoradiation. Most patients need palliative treatment. Once pancreatic cancer becomes metastatic, it is uniformly fatal with an overall survival of generally 6 months from time of diagnosis. Gemcitabine has been the standard since 1997. FOLFIRINOX (5-fluorouracil, oxaliplatin, irinotecan, leucovorin) has already shown superiority over gemcitabine in both progression-free survival and overall survival, but this regimen is suitable only for selected patients in ECOG performance status 0-1. FOLFIRINOX has already trickled down to the clinic in various modifications and in different patient groups, both locally advanced and metastatic. Many targeted agents, including bevacizumab, cetuximab showed negative results, except mild benefit with addition of erlotinib with gemcitabine, which was not considered clinically significant. There is no consensus regarding treatment in the second-line setting. It will be true to say that there was a real medical breakthrough with regards to improving the prognosis of pancreatic cancer as of 2013 with the results of MPACT study. In this study, patients who received nab-paclitaxel plus gemcitabine lived a median of 8.5 months, compared with 6.7 months for those who received gemcitabine alone. At the end of one year, 35% of those getting nab-paclitaxel were alive, compared with 22% of those getting only gemcitabine. After two years, the figures were 9% for those getting nab-paclitaxel and 4% for those who received gemcitabine.

380 Editorial Lost in the supermarket. 2013

Jacobs, Howy. · ·EMBO Rep · Pubmed #23455353.

ABSTRACT: -- No abstract --

381 Editorial Circulating molecular markers in pancreatic cancer: ready for clinical use? 2013

Gall, Tamara M H / Frampton, Adam E / Krell, Jonathan / Castellano, Leandro / Jiao, Long R. · ·Future Oncol · Pubmed #23414463.

ABSTRACT: -- No abstract --

382 Editorial Pancreatic cancer screening: what we do and do not know. 2013

Bhutani, Manoop S / Thosani, Nirav / Suzuki, Rei / Guha, Sushovan. · ·Clin Gastroenterol Hepatol · Pubmed #23403010.

ABSTRACT: -- No abstract --

383 Editorial Biliary findings and the neoplastic potential of branch duct intraductal papillary mucinous neoplasm. 2013

Buxbaum, James L / Eloubeidi, Mohamad A. · ·Clin Gastroenterol Hepatol · Pubmed #23395700.

ABSTRACT: -- No abstract --

384 Editorial Hepatobiliary cancer and pyogenic liver abscess: when poking the skunk is not enough: invited commentary on Chen, et al. Am J Surg 2013;205:52-7. 2013

Behrns, Kevin E. · ·Am J Surg · Pubmed #23375754.

ABSTRACT: -- No abstract --

385 Editorial Pancreatic extragastrointestinal stromal tumors, interstitial Cajal like cells, and telocytes. 2013

Padhi, Somanath / Sarangi, Rajlaxmi / Mallick, Saumyaranjan. · ·JOP · Pubmed #23306329.

ABSTRACT: CONTEXT: The discovery and subsequent ultrastructural characterization of the interstitial Cajal like cells (now called telocytes) in virtually every anatomic sites of the human body, by Laurentiu M Popescu and co-workers, have dramatically improved the understanding the function of these cells and pathogenesis of extragastrointestinal stromal tumors (EGIST). Pancreatic extragastrointestinal stromal tumors (pEGIST), phenotypically similar to pancreatic interstitial Cajal like cells, are extremely rare with an unpredictable biological behavior. OBJECTIVE: To review the clinicopathological, radiological, immunohistochemical, and therapeutic outcome data of all reported cases of pEGIST, and highlight the developments in the field of pancreatic interstitial Cajal like cells/telocytes. METHODS: A systematic review of English literature (January 2000 to July 2012) was done by using the search engine of PubMed, PubMed Central, Google Scholar, and the Directory of Open Access Journals. RESULTS: There have been 19 reported cases of pEGIST during the last decade, over an age range of 31 to 84 years (mean: 56 years) with equal gender predilection ((male:female ratio: 9:10). Preoperative radiological characteristics have been mostly nondiagnostic though these were used, in some, for tissue diagnosis. Majority of pEGIST were localized to pancreatic head (8/19, 42.1%), and 15 of 19 patients (78.9%) were symptomatic at first presentation. The mean size ranged from 2.5 to 35cm (mean: 14 cm). Histomorphological features were that of predominantly spindle cell tumor which consistently expressed c-KIT/CD117 and CD34 by immunohistochemistry, making these two as the most sensitive markers at this site. RESULTS: from studies involving discovery on gastrointestinal stromal tumor 1 (DOG-1), the most specific biomarker of GIST/EGIST, has been inconclusive and this was found to be positive in one case only. Neoadjuvant chemotherapy with imatinib mesylate and sunitinib were used in few cases, and genetic analysis of c-KIT proto-oncogene was done in two. By univariate analysis, none of the clinicopathological parameters, except surgical resection with microscopic free margin (R0 resection) (P<0.05), were found to be an important indicators of outcome. CONCLUSION: The biological behavior of pEGIST, at present, seems unpredictable which requires indefinite period of follow-up. Large number of such cases with genetic analysis supplemented with immunohistochemistry studies will hopefully throw more light in these tumors.

386 Editorial Plasma adiponectin: a possible link between fat metabolism and pancreatic cancer risk. 2013

Zhang, Jianliang / Hochwald, Steven N. · ·J Natl Cancer Inst · Pubmed #23243204.

ABSTRACT: -- No abstract --

387 Editorial Achieving the best of both worlds. 2013

Ko, Andrew H / Cella, David. · ·J Clin Oncol · Pubmed #23213099.

ABSTRACT: -- No abstract --

388 Editorial Is personalization of care coming to pancreatic oncology? 2013

Crane, Christopher H. · ·Ann Surg Oncol · Pubmed #23188544.

ABSTRACT: -- No abstract --

389 Editorial Cost-effectiveness of treatment strategies for primary operable pancreatic head adenocarcinoma: do we have more scientific evidence to call for further centralization of care? 2013

Gajdos, Csaba / Schulick, Richard. · ·Ann Surg Oncol · Pubmed #23054108.

ABSTRACT: -- No abstract --

390 Editorial Gastroenteropancreatic neuroendocrine tumors (GEP-NETs). 2012

de Herder, Wouter W. · ·Best Pract Res Clin Gastroenterol · Pubmed #23582912.

ABSTRACT: -- No abstract --

391 Editorial From the guest editor please join us in this honorable quest. 2012

Yeo, Charles J. · ·Cancer J · Pubmed #23187832.

ABSTRACT: -- No abstract --

392 Editorial KRAS above and beyond - EGFR in pancreatic cancer. 2012

Siveke, Jens T / Crawford, Howard C. · ·Oncotarget · Pubmed #23174662.

ABSTRACT: -- No abstract --

393 Editorial Ki67 labeling index in neuroendocrine tumors of the gastrointestinal and pancreatobiliary tract: to count or not to count is not the question, but rather how to count. 2012

Adsay, Volkan. · ·Am J Surg Pathol · Pubmed #23154766.

ABSTRACT: -- No abstract --

394 Editorial Endoscopic ultrasound guided fine needle aspiration: results are reproducible. 2012

Almadi, Majid A / Barkun, Alan N. · ·Saudi J Gastroenterol · Pubmed #23150018.

ABSTRACT: -- No abstract --

395 Editorial Pancreatic ductal adenocarcinoma screening: new perspectives. 2012

Pezzilli, Raffaele / Fabbri, Dario / Imbrogno, Andrea. · ·World J Gastroenterol · Pubmed #23049204.

ABSTRACT: Pancreatic ductal adenocarcinoma accounts for more than 90% of all pancreatic cancers and its incidence has increased significantly worldwide. Patients with pancreatic ductal adenocarcinoma have a poor outcome and more than 95% of the people affected die from the disease within 12 mo after diagnosis. Surgery is the first-line treatment in the case of resectable neoplasm, but only 20% of patients are candidates for this approach. One of the reasons there are few candidates for surgery is that, during the early phases of the disease, the symptoms are poor or non-specific. Early diagnosis is of crucial importance to improve patient outcome; therefore, we are looking for a good screening test. The screening test must identify the disease in an early stage in order to be effective; having said this, a need exists to introduce the concept of "early" ductal adenocarcinoma. It has been reported that at least five additional years after the occurrence of the initiating mutation are required for the acquisition of metastatic ability of pancreatic adenocarcinoma and patients die an average of two years thereafter. We have reviewed the most recent literature in order to evaluate the present and future perspectives of screening programs of this deadly disease.

396 Editorial Keys to personalized care in pancreatic oncology. 2012

Crane, Christopher H / Iacobuzio-Donahue, Christine A. · ·J Clin Oncol · Pubmed #23045599.

ABSTRACT: -- No abstract --

397 Editorial Progress in pancreatic cancer: moving beyond gemcitabine? 2012

Basu, Bristi / Jodrell, Duncan. · ·Expert Rev Anticancer Ther · Pubmed #23030218.

ABSTRACT: -- No abstract --

398 Editorial Role of taxanes in pancreatic cancer. 2012

Belli, Carmen / Cereda, Stefano / Reni, Michele. · ·World J Gastroenterol · Pubmed #22969215.

ABSTRACT: Pancreatic cancer is one of the most deadly cancers and is characterized by a poor prognosis. Single agent gemcitabine, despite its limited activity and modest impact on disease outcome, is considered as the standard therapy in pancreatic cancer. Most of the combination regimens used in the treatment of this disease, also including the targeted agents, did not improve the outcome of patients. Also, taxanes have been tested as single agent and in combination chemotherapy, both in first line and as salvage chemotherapy, as another possible option for treating pancreatic cancer. The inclusion of taxanes in combination with gemcitabine as upfront therapy obtained promising results. Accordingly, taxanes, and above all, new generation taxanes, appear to be suitable candidates for further testing to assess their role against pancreatic cancer in various clinical settings.

399 Editorial Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment. 2012

Danquah, Michael / Singh, Saurabh / Behrman, Stephen W / Mahato, Ram I. · ·Expert Opin Drug Deliv · Pubmed #22954290.

ABSTRACT: -- No abstract --

400 Editorial Age and pancreaticoduodenctomy: is it really about mortality? 2012

Connor, Saxon / Sakowska, Magdalena. · ·HPB (Oxford) · Pubmed #22953999.

ABSTRACT: -- No abstract --

Back · Next